TY  - JOUR
AU  - Miletić Vukajlović, Jadranka
AU  - Drakulić, Dunja
AU  - Pejić, Snežana
AU  - Ilić, Tihomir V.
AU  - Stefanović, Aleksandra
AU  - Petković, Marijana
AU  - Schiller, Jürgen
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3522
AB  - Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration.
PB  - John Wiley and Sons Ltd
T2  - Rapid Communications in Mass Spectrometry
T1  - Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease
VL  - 34
IS  - 4
DO  - 10.1002/rcm.8595
ER  - 

@article{
author = "Miletić Vukajlović, Jadranka and Drakulić, Dunja and Pejić, Snežana and Ilić, Tihomir V. and Stefanović, Aleksandra and Petković, Marijana and Schiller, Jürgen",
year = "2020",
abstract = "Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration.",
publisher = "John Wiley and Sons Ltd",
journal = "Rapid Communications in Mass Spectrometry",
title = "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease",
volume = "34",
number = "4",
doi = "10.1002/rcm.8595"
}

Miletić Vukajlović, J., Drakulić, D., Pejić, S., Ilić, T. V., Stefanović, A., Petković, M.,& Schiller, J.. (2020). Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry
John Wiley and Sons Ltd., 34(4).
https://doi.org/10.1002/rcm.8595

Miletić Vukajlović J, Drakulić D, Pejić S, Ilić TV, Stefanović A, Petković M, Schiller J. Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry. 2020;34(4).
doi:10.1002/rcm.8595 .

Miletić Vukajlović, Jadranka, Drakulić, Dunja, Pejić, Snežana, Ilić, Tihomir V., Stefanović, Aleksandra, Petković, Marijana, Schiller, Jürgen, "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease" in Rapid Communications in Mass Spectrometry, 34, no. 4 (2020),
https://doi.org/10.1002/rcm.8595 . .

TY  - THES
AU  - Miletić Vukajlović, Jadranka
PY  - 2019
UR  - http://nardus.mpn.gov.rs/handle/123456789/12188
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=7339
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:21576/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=2048435554
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3700
AB  - Parkinsonova bolest (PB) je hronična neurodegenerativna bolest koja nastaje usled poremećaja multiplih neurotransmitera, između kojih prednjači nedostatak dopamina u delu mozga u kome se nalaze centri za izvođenje voljnih pokreta. Iako je PB predmet mnogobrojnih dugogodišnjih istraživanja, tačna etiopatologija je nepoznata. Pretpostavlja se da je pored različitih faktora, jedan od ključnih uzročnika njenog nastanka i progresije prekomerna produkcija reaktivnih kiseoničnih i azotnih vrsta i narušen kapacitet njihovog uklanjanja koje mogu pokrenuti kaskadu promena i izazivati oštećenja biomolekula, poput proteina i lipida.Cilj ovog istraživanja bio je da se identifikuju potencijalni biomarkeri za evaluaciju stanja pacijenata obolelih od PB praćenjem promena parametara oksidativnog stresa (OS) (prooksidativni-antioksidativni balans (PAB), produkti oksidovane modifikacije proteina (AOPP), 4-hidroksinonenal (HNE), malondialdehid (MDA)), odnosa intenziteta pikova fosfatidilholina (PC) i lizofosfatidilholina (LPC), kao i parametara antioksidativne (AO) zaštite (superoksid dizmutaza (SOD), katalaze (CAT) i glutationa (GSH)) u zavisnosti od kliničko-patoloških karakteristika (pola, starosti, Hoehn i Yahr (H&Y) stadijuma i dužine trajanja bolesti). Takođe, proučavan je i efekat terapije na ispitivane parametre. Studija je obuhvatila ispitanike, kontrole i pacijente sa PB utvrđenom prema dijagnostičkom kriterijumu UK PB Society Brain Bank Research criteria. Promene parametara OS i AO zaštite kod 111 ispitanika (20 kontrola i 91 pacijenta) su praćenje pomoću spektrofotometrijskih metoda i imunoblot tehnikom, dok je lipidni profil kod 35 ispitanika (10 kontrola i 25 pacijenata) određivan MALDI TOF (eng. Matrix Assisted Laser Desorption and Ionization Time Of Flight) masenom spektrometrijom što ujedno predstavlja prvo ispitivanje PC/LPC inteziteta kod pacijenata sa PB.Analiza ispitivanih parametara ukazuje na povećan nivo svih OS parametara, kao i poremećenu AO zaštitu i narušen lipidni profil pacijenata sa PB, ali i na njihovu vezu sa kliničko-patološkim karakteristikama. Sa druge strane, uticaj doze i tipa terapije nije uočen ni na jednom od ispitivanih parametara. Dobijeni rezultati sugerišu da se ispitivani parametri OS i AO zaštite mogu koristiti kaopotencijalni markeri u evaluaciji stanja pacijenata obolelih od PB, dokuočene promene PC/LPC intenziteta pikova mogu poslužiti kao jedan od prvih koraka u karakterizaciji lipidnog profila pacijenata sa PB kao pokazateljistrukturnih lipidnih rekonfiguracija.
AB  - Parkinson's disease (PD) is a chronic neurodegenerative disease assosiated with alteration of multiple neurotransmitters, including dopamine deficiency, in the brain region responsible for voluntary movement. Although PD has been subject of many studies over the years, the underlying etiopathology still remains unknown. PD onset and progression might be a consequence of the overproduction of reactive oxygen and nitrogen species and impaired capacity for their removal that could initiate a cascade of events and induce damage of biomolecules, including proteins and lipids.The aim of current study was to identify potential biomarkers for the evaluation of patients with PD by monitoring changes of oxidative stress (OS) parameters (pro-oxidant-antioxidant balance (PAB), advanced oxidized protein products (AOPP), 4-hydroxynonenal (HNE), malondialdehyde (MDA)), phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) peak intensity ratios, along with antioxidant (AO) defence parameters (superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH)) and their relation to clinical and pathological characteristics (such as gender, age at examination, duration of the disease, and Hoehn and Yahr (H&Y) score). Furthermore, the effect of therapy (dose and type) on the examined parameters was also studied. The study included controls and patients with PD determined by the diagnostic criteria of the UK PB Society Brain Bank Research criteria. Changes in parameters of OS and AO defence in 111 subjects (20 controls and 91 patients) were monitored using spectrophotometric methods and immunoblot technique, while the lipid profile in 35 subjects (10 controls and 25 patients) was determined by MALDI TOF (Matrix Assisted Laser Desorption and Ionization Time Of Flight) mass spectrometry which represents the first attempt to investigate PC/LPC intensity ratio in plasma of PD patients.The obtained results revealed the increased levels of investigated OS parameters along with an altered AO defence response and imparied lipid profile of PD patients and their relationship with clinic-pathological characteristics. Moreover, dose and type of therapy had no influence on any investigated parameter. According to presented results, investigated parameters of OS and AO defence might be used  to  evaluate  the  condition  of PD patients,  while the observed  changes  of  PC/LPC intensity  might  serve  as  one  of  the  first  steps  in  characterizing  the  lipid  profile  of PD patients being amark of structural lipid reconfigurations.
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Ispitivanje zavisnosti lipidnog sastava plazme i parametara lipidne peroksidacije od stadijuma i dužine trajanja Parkinsonove bolesti i primene terapije
UR  - https://hdl.handle.net/21.15107/rcub_nardus_12188
ER  - 

@phdthesis{
author = "Miletić Vukajlović, Jadranka",
year = "2019",
abstract = "Parkinsonova bolest (PB) je hronična neurodegenerativna bolest koja nastaje usled poremećaja multiplih neurotransmitera, između kojih prednjači nedostatak dopamina u delu mozga u kome se nalaze centri za izvođenje voljnih pokreta. Iako je PB predmet mnogobrojnih dugogodišnjih istraživanja, tačna etiopatologija je nepoznata. Pretpostavlja se da je pored različitih faktora, jedan od ključnih uzročnika njenog nastanka i progresije prekomerna produkcija reaktivnih kiseoničnih i azotnih vrsta i narušen kapacitet njihovog uklanjanja koje mogu pokrenuti kaskadu promena i izazivati oštećenja biomolekula, poput proteina i lipida.Cilj ovog istraživanja bio je da se identifikuju potencijalni biomarkeri za evaluaciju stanja pacijenata obolelih od PB praćenjem promena parametara oksidativnog stresa (OS) (prooksidativni-antioksidativni balans (PAB), produkti oksidovane modifikacije proteina (AOPP), 4-hidroksinonenal (HNE), malondialdehid (MDA)), odnosa intenziteta pikova fosfatidilholina (PC) i lizofosfatidilholina (LPC), kao i parametara antioksidativne (AO) zaštite (superoksid dizmutaza (SOD), katalaze (CAT) i glutationa (GSH)) u zavisnosti od kliničko-patoloških karakteristika (pola, starosti, Hoehn i Yahr (H&Y) stadijuma i dužine trajanja bolesti). Takođe, proučavan je i efekat terapije na ispitivane parametre. Studija je obuhvatila ispitanike, kontrole i pacijente sa PB utvrđenom prema dijagnostičkom kriterijumu UK PB Society Brain Bank Research criteria. Promene parametara OS i AO zaštite kod 111 ispitanika (20 kontrola i 91 pacijenta) su praćenje pomoću spektrofotometrijskih metoda i imunoblot tehnikom, dok je lipidni profil kod 35 ispitanika (10 kontrola i 25 pacijenata) određivan MALDI TOF (eng. Matrix Assisted Laser Desorption and Ionization Time Of Flight) masenom spektrometrijom što ujedno predstavlja prvo ispitivanje PC/LPC inteziteta kod pacijenata sa PB.Analiza ispitivanih parametara ukazuje na povećan nivo svih OS parametara, kao i poremećenu AO zaštitu i narušen lipidni profil pacijenata sa PB, ali i na njihovu vezu sa kliničko-patološkim karakteristikama. Sa druge strane, uticaj doze i tipa terapije nije uočen ni na jednom od ispitivanih parametara. Dobijeni rezultati sugerišu da se ispitivani parametri OS i AO zaštite mogu koristiti kaopotencijalni markeri u evaluaciji stanja pacijenata obolelih od PB, dokuočene promene PC/LPC intenziteta pikova mogu poslužiti kao jedan od prvih koraka u karakterizaciji lipidnog profila pacijenata sa PB kao pokazateljistrukturnih lipidnih rekonfiguracija., Parkinson's disease (PD) is a chronic neurodegenerative disease assosiated with alteration of multiple neurotransmitters, including dopamine deficiency, in the brain region responsible for voluntary movement. Although PD has been subject of many studies over the years, the underlying etiopathology still remains unknown. PD onset and progression might be a consequence of the overproduction of reactive oxygen and nitrogen species and impaired capacity for their removal that could initiate a cascade of events and induce damage of biomolecules, including proteins and lipids.The aim of current study was to identify potential biomarkers for the evaluation of patients with PD by monitoring changes of oxidative stress (OS) parameters (pro-oxidant-antioxidant balance (PAB), advanced oxidized protein products (AOPP), 4-hydroxynonenal (HNE), malondialdehyde (MDA)), phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) peak intensity ratios, along with antioxidant (AO) defence parameters (superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH)) and their relation to clinical and pathological characteristics (such as gender, age at examination, duration of the disease, and Hoehn and Yahr (H&Y) score). Furthermore, the effect of therapy (dose and type) on the examined parameters was also studied. The study included controls and patients with PD determined by the diagnostic criteria of the UK PB Society Brain Bank Research criteria. Changes in parameters of OS and AO defence in 111 subjects (20 controls and 91 patients) were monitored using spectrophotometric methods and immunoblot technique, while the lipid profile in 35 subjects (10 controls and 25 patients) was determined by MALDI TOF (Matrix Assisted Laser Desorption and Ionization Time Of Flight) mass spectrometry which represents the first attempt to investigate PC/LPC intensity ratio in plasma of PD patients.The obtained results revealed the increased levels of investigated OS parameters along with an altered AO defence response and imparied lipid profile of PD patients and their relationship with clinic-pathological characteristics. Moreover, dose and type of therapy had no influence on any investigated parameter. According to presented results, investigated parameters of OS and AO defence might be used  to  evaluate  the  condition  of PD patients,  while the observed  changes  of  PC/LPC intensity  might  serve  as  one  of  the  first  steps  in  characterizing  the  lipid  profile  of PD patients being amark of structural lipid reconfigurations.",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Ispitivanje zavisnosti lipidnog sastava plazme i parametara lipidne peroksidacije od stadijuma i dužine trajanja Parkinsonove bolesti i primene terapije",
url = "https://hdl.handle.net/21.15107/rcub_nardus_12188"
}

Miletić Vukajlović, J.. (2019). Ispitivanje zavisnosti lipidnog sastava plazme i parametara lipidne peroksidacije od stadijuma i dužine trajanja Parkinsonove bolesti i primene terapije. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_12188

Miletić Vukajlović J. Ispitivanje zavisnosti lipidnog sastava plazme i parametara lipidne peroksidacije od stadijuma i dužine trajanja Parkinsonove bolesti i primene terapije. in Универзитет у Београду. 2019;.
https://hdl.handle.net/21.15107/rcub_nardus_12188 .

Miletić Vukajlović, Jadranka, "Ispitivanje zavisnosti lipidnog sastava plazme i parametara lipidne peroksidacije od stadijuma i dužine trajanja Parkinsonove bolesti i primene terapije" in Универзитет у Београду (2019),
https://hdl.handle.net/21.15107/rcub_nardus_12188 .